Oligodendrogliomas: Clinical significance of 1p and 19q chromosomal deletions

Adam M. Sonabend, Maciej S. Lesniak*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

8 Scopus citations


Oligodendrogliomas are a distinct subgroup of brain tumors with a fairly favorable clinical prognosis. However, these tumor exhibit varying degrees of heterogeneity and their clinical behavior is therefore not always the same. For this reason, genetic markers have been developed to further guide the clinical treatment. One such marker, the 1p and 19q chromosomal deletions, has been well documented in a subset of patients with oligodendrogliomas. Most importantly, patients who exhibit these chromosomal deletions respond favorably to chemotherapy. This article reviews the evidence describing the association of such deletions with a favorable response to chemotherapy and improved prognosis of patients with oligodendrogliomas. In addition, attempts to elucidate the molecular mechanisms behind the biologic behavior of these tumors are further explored.

Original languageEnglish (US)
JournalExpert Review of Neurotherapeutics
Issue number6 SUPPL.
StatePublished - Nov 1 2005


  • 19q
  • 1p
  • Anaplastic oligodendroglioma
  • Chemotherapy
  • Chromosomal deletions
  • Low-grade glioma
  • Oligodendroglioma

ASJC Scopus subject areas

  • Neuroscience(all)
  • Clinical Neurology
  • Pharmacology (medical)


Dive into the research topics of 'Oligodendrogliomas: Clinical significance of 1p and 19q chromosomal deletions'. Together they form a unique fingerprint.

Cite this